Form 4: Royalty Pharma EVP Urist Reports Share Transactions

Royalty Pharma plc's EVP of Research & Investments, Marshall Urist, reported the acquisition of Class A Ordinary Shares from equity awards and an exchange of limited partnership interests for Class A Ordinary Shares.

Summary

• Marshall Urist, EVP, Research & Investments at Royalty Pharma plc, reported changes in his beneficial ownership of Class A Ordinary Shares.
• On November 5, 2025, Mr. Urist acquired 4,626 Class A Ordinary Shares through the settlement of Equity Performance Awards, an exempt transaction under Rule 16b-3.
• On November 7, 2025, Mr. Urist exchanged 16,000 limited partnership interests in RPI US Partners 2019, LP for 160,000 Class A Ordinary Shares of Royalty Pharma plc.
• This exchange involved converting each LP interest into ten Class B Interests in Royalty Pharma Holdings Limited, which were then exchanged for one Class A Ordinary Share each, with no additional value paid by Mr. Urist.
• Following these transactions, Mr. Urist directly owns 43,882 Class A Ordinary Shares and indirectly owns 206,667 Class A Ordinary Shares via Sandy Lamm LLC and 19,020 via an IRA.
• Additionally, Mr. Urist indirectly beneficially owns 247,412 derivative securities (RPI US LP Interests) via Sandy Lamm LLC, which are convertible into Class A Ordinary Shares.

Sentiment

Score: 7

Explanation: The increase in beneficial ownership by a key executive, even through non-cash transactions, generally signals confidence in the company's future and aligns management's interests with shareholders.

Positives

• Marshall Urist, a key executive, increased his beneficial ownership of Royalty Pharma plc Class A Ordinary Shares by 4,626 shares through equity performance awards and 160,000 shares through an exchange of LP interests.
• This increase in shareholding aligns the executive's interests more closely with those of shareholders.

Negatives

• The reported share acquisitions were not open market purchases for cash, but rather through equity awards and an exchange mechanism, which does not represent new capital investment by the executive.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

This is a routine insider transaction report, common for publicly traded companies, reflecting changes in executive shareholdings due to compensation or pre-arranged exchange agreements. It does not provide broader industry context.

Related Party Transactions

• The exchange of limited partnership interests in RPI US Partners 2019, LP for Class A Ordinary Shares of Royalty Pharma plc is a pre-arranged transaction mechanism detailed in the Amended and Restated Exchange Agreement, representing a standard conversion process for RPRX's corporate structure.

Stakeholder Impact

• Shareholders may view the increased beneficial ownership by a key executive as a positive sign, indicating management's continued alignment with shareholder interests and confidence in the company's long-term prospects.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions involving equity awards and an exchange of partnership interests for shares. While it shows an increase in a key executive's beneficial ownership, it does not involve open market purchases or significant new capital investment, nor does it contain new material information that would warrant a change in investment recommendation. It is a standard disclosure of executive compensation and ownership structure.

Keywords

Royalty Pharma, RPRX, Insider Transaction, Form 4, Beneficial Ownership, Equity Awards, Share Exchange, Marshall Urist